The regulatory landscape for actively personalized cancer immunotherapies

To the Editor: Genetic heterogeneity is a hallmark of cancer. Distinct genotypes are found for individual tumors and even within single lesions1, 2. This heterogeneity and the high diversity of the overall constitution of individual patients demand tailored approaches in tumor therapy. The promise of new approaches categorized as personalized medicine… Download references